CoChat

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

Smith, Mitchell R · 2003 · Oncogene

Abstract

Rituximab, a chimeric monoclonal antibody targeted against the pan-B-cell marker CD20, was the first monoclonal antibody to be approved for therapeutic use. Treatment with rituximab at standard weekly dosing is effective in more than 50% of patients with relapsed or refractory CD20-positive follicular non-Hodgkin's lymphoma, but is not curative. It is less effective in other subtypes of CD20-positive lymphoma and for retreatment, even with CD20 still expressed. Thus, binding of rituximab to CD20 is not sufficient to kill many lymphoma cells, indicating that there are mechanisms of resistance. Mechanisms of cell destruction that have been demonstrated to be activated by rituximab binding to CD20 include direct signaling of apoptosis, complement activation and cell-mediated cytotoxicity. The relative importance of each of these mechanisms in determining clinical response to rituximab treatment remains a matter of conjecture. Thus, the role of various resistance pathways, some documented in experimental systems and others still hypothetical, remains uncertain. Resistance could potentially be mediated by alterations in CD20 expression or signaling, elevated apoptotic threshold, modulation of complement activity or diminished cellular cytotoxicity. As the first of an expanding class of anticancer agents, lessons learned regarding the mechanism of rituximab action and resistance will be of increasing importance.

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.onc.1206939

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 62 references

Research works printed but not linked: 1

  1. Witzig TE, Flinn IW, Gordon LI, Emmanouilldes C, Czuczman MS, Saleh MN, Cripe L, Wiseman G, Olejnik T, Multani PS and White CA . (2002b). J. Clin. Oncol., 20, 2453–2463. · DOI · Paper page

Cited by

See all 854

Metadata

Authors
Smith, M. R.
Affiliations
Fox Chase Cancer Center (US)
Corresponding author
Smith, Mitchell R
Venue
Oncogene
Published
2003-10-20
Volume
22
Issue
47
Pages
7359-7368
ISSN
  • 0950-9232 (ISSN-L)
  • 1476-5594
OpenAlex
W2088332148
Cited by
835
References
62
Citations by year
2026: 30 · 2025: 45 · 2024: 33 · 2023: 37 · 2022: 49 · 2021: 64 · 2020: 33 · 2019: 37 · 2018: 32 · 2017: 36 · 2016: 33 · 2015: 35 · 2014: 28 · 2013: 32 · 2012: 31
FWCI
3.80
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Oncogene (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords
rituximab, CD20, monoclonal antibodies, follicular non-Hodgkin's lymphoma, drug resistance, apoptosis signaling, complement activation, cell-mediated cytotoxicity, CD20 expression, B-cell lymphoma, mechanism of action
MeSH terms
Rituximab, Antibodies, Monoclonal, Antigen-Antibody Reactions, Humans, Radioimmunotherapy, Treatment Outcome, Apoptosis, Antigens, CD20, Drug Resistance, Neoplasm, Antibodies, Monoclonal, Murine-Derived

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. https://app.cochat.ai/papers/10.1038/sj.onc.1206939
The paper
Smith, M. R. (2003). Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. https://doi.org/10.1038/sj.onc.1206939

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.